Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pandion PT-101 single-cell RNA-seq of CD122+ non-myeloid cells following IL-2 mutein treatment

ABSTRACT: This study uses samples from the Pandion Phase 1a IL-2 mutein (PT-101) trial to investigate the mechanism of action of IL-2 mutein therapy. IL-2 mutein is engineered for increased affinity for CD25 and decreased affinity for CD122, selectively activating regulatory T cells (Tregs) while limiting stimulation of CD122-expressing effector populations (NK cells, ILCs, and CD122+ T cells). This dataset addresses whether the highest tested dose (10mg) induces an undesirable, off-target transcriptional signature in CD122+ non-myeloid cells. Single-cell RNA-seq (10x Genomics Chromium) was performed on FACS-sorted CD122+ cells from PBMC of 4 subjects in the 10mg dose cohort, at baseline (pre-treatment) and Day 8 post-dose, to assess treatment-induced changes in cell cluster composition and gene expression at single-cell resolution.

ORGANISM(S): Homo sapiens

PROVIDER: GSE338670 | GEO | 2026/07/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Pandion PT-101 single-cell RNA-seq of CD122+ non-myeloid cells following IL-2 mutein treatment

Project description:Pandion PT-101 single-cell RNA-seq of CD122+ non-myeloid cells following IL-2 mutein treatment

| PRJNA1495365 | ENA

Bulk RNAseq of sorted Treg cells from a single ascending dose clinical trial in healthy adults of IL-2 mutein MK-6194 (formerly known as PT-101)

Project description:The objectives are to use cryopreserved PBMC samples from the Phase 1a single ascending dose trial of IL-2 mutein (MK-6194/PT-101) in healthy adults to define the transcriptional responses of regulatory CD4+ T cells (CD25hiCD127lo Treg), and determine how this varies with both dose and time after treatment.

2026-07-30 | GSE338655 | GEO

Microarray data from uterine CD122+ macrophages

Project description:IL-15-responsive CD122+ macrophages (CD122+Macs) develop in the uterus during normal pregnancy. We aimed to understand the signals driving macrophages to adopt this fate. We aimed to determine how CD122+Macs and conventional uterine macrophages differ transcriptionally.

2020-06-08 | GSE132353 | GEO

Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein

Project description:Interleukin-2 (IL-2) is critical for regulatory T cell (Treg) function and homeostasis. At low doses, IL-2 can suppress immune pathologies by expanding Tregs that constitutively express the high affinity IL-2Rα subunit. However, even low doses IL-2, signaling through the IL2-Rβ/γ complex, may lead to the activation of proinflammatory, non-Treg T cells, so improving specificity toward Tregs may be desirable. Here we used messenger RNAs (mRNA) to encode a half-life-extended human IL-2 mutein (HSA-IL2m) with mutations promoting reliance on IL-2Rα. Our data show that IL-2 mutein subcutaneous delivery in lipid-encapsulated mRNA nanoparticles selectively activates and expands Tregs in mice and non-human primates, as well as reduces disease severity in mouse models of acute graft versus host disease and experimental autoimmune encephalomyelitis. Single cell RNA sequencing of murine splenic CD4+ T cells identifies multiple Treg states with distinct response dynamics following IL-2 mutein treatment. Our results thus demonstrate the potential of mRNA-encoded HSA-IL2m immunotherapy to treat autoimmune diseases.

2022-04-07 | GSE200142 | GEO

IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein (RNA-Seq)

Project description:Cytokines interact with their receptors in the extracellular space to control immune responses. How the physicochemical properties of the extracellular space influence cytokine signaling is incompletely elucidated. Here, we show that the activity of interleukin (IL)-2, a critical cytokine in T cell immunity, is profoundly affected by pH, limiting IL-2 signaling within the acidic environment of tumors. Generation of lactic acid by tumors limits STAT5 activation, effector differentiation and anti-tumor immunity by CD8+ T cells and renders high-dose IL-2 therapy poorly effective. Directed evolution enabled selection of a pH-selective IL-2 mutein (Switch-2). Switch-2 binds the IL-2 receptor subunit IL-2Ra with higher affinity, triggers STAT5 activation and drives CD8+ T cell effector function more potently at acidic pH than at neutral pH. Consequently, high-dose Switch-2 therapy induces potent immune activation and tumor rejection with reduced on-target toxicity in normal tissues. Finally, we find that sensitivity to pH is a generalizable property of a diverse range of cytokines with broad relevance to immunity and immunotherapy in healthy and diseased tissues.

2022-12-02 | GSE213439 | GEO

IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein (scRNA-Seq)

2022-12-02 | GSE213440 | GEO

Mouse CD8+CD122+ regulatory T cells

Project description:Gene expression profile was compared between CD8+CD122+ T cells and CD8+CD122- T cells. mRNA taken from CD8+CD122+ cells or CD8+CD122- cells collected by cell sorting from C57BL/6 mice spleen was amplified and analyzed by using gene chip of Agilent.

2008-12-30 | E-GEOD-13890 | biostudies-arrayexpress

An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells [RNA-seq]

Project description:Interleukin-2 (IL-2) variants with increased CD25 dependence that selectively expand Foxp3+ regulatory T (TR) cells are in clinical trials for treating inflammatory diseases. Using an Fc-fused IL-2 mutein (Fc.IL-2 mutein) we developed that prevents diabetes in non-obese diabetic (NOD) mice, we show that Fc.IL-2 mutein induced an activated TR population with elevated proliferation, a transcriptional program associated with Stat5- and TCR-dependent gene modules, and high IL-10 and CTLA-4 expression. Increased IL-10 signaling limited surface MHC class II upregulation during conventional dendritic cell (cDC) maturation, while increased CTLA-4-dependent transendocytosis led to the transfer of CD80 and CD86 costimulatory ligands from maturing cDCs to TR cells. In NOD mice, Fc.IL-2 mutein treatment promoted the suppression of cDCs in the inflamed pancreas and pancreatic lymph nodes resulting in T cell anergy. Thus, IL-2 mutein-expanded TR cells have enhanced functional properties and restrict cDC function, offering promise for targeted immunotherapy use in autoimmune disease.

2023-12-08 | GSE249186 | GEO

Mouse CD8+CD122+ regulatory T cells

Project description:Gene expression profile was compared between CD8+CD122+ T cells and CD8+CD122- T cells.

2008-12-31 | GSE13890 | GEO

An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells [10x scRNA-seq]

Project description:Interleukin-2 (IL-2) variants with increased CD25 dependence that selectively expand Foxp3+ regulatory T (TR) cells are under clinical investigation for treating autoimmune and inflammatory diseases. We previously described an Fc-fused CD25-biased IL-2 mutein (Fc.IL-2 mutein) that promotes TR expansion and prevents the onset of autoimmune diabetes in non-obese diabetic (NOD) mice; however, the effects of this treatment on TR function in vivo are unclear. Here we show that Fc.IL-2 mutein treatment induces an activated Foxp3+ TR population characterized by elevated proliferation, a unique transcriptional program associated with Stat5- and TCR-dependent gene modules, and high levels of the immunosuppressive molecules IL-10 and CTLA-4. Increased IL-10 receptor signaling limits the upregulation of surface MHC class II expression during conventional dendritic cell (cDC) maturation, while increased CTLA-4-dependent transendocytosis leads to the transfer of CD80 and CD86 costimulatory ligands from maturing cDCs to Tregs. In NOD mice, Fc.IL-2 mutein treatment resulted in TR-mediated regulation of cDCs in the inflamed pancreas and draining lymph nodes accompanied by an increase in anergic T cells. Thus, we demonstrate that IL-2 mutein-expanded TR cells have enhanced functional properties and potently act to restrict cDC function in the target tissue and at the site of autoimmune induction, offering promising prospects for targeted immunotherapy.

2023-12-08 | GSE249481 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data